AzTrials
AzTrials

Degenerative Lumbar SpondylolisthesisDS-registryNCT03469791

Degenerative Spondylolisthesis; Micro-decompression vs Decompression + Instrumented Fusion; Long Term Follow up

A study testing Surgical treatment of Degenerative Spondylolisthesis in people with Degenerative Lumbar Spondylolisthesis, run by Haukeland University Hospital at 1 site in Norway.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

In many countries a majority of patients with degenerative spondylolisthesis are operated on with decompression plus instrumented fusion, but the scientific evidence for adding fusion is controversial. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Degenerative Lumbar Spondylolisthesis
What is being tested?
Surgical treatment of Degenerative Spondylolisthesis
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
426 participants
Where
1 siteNorway
Study dates
1 Sep 2007to 31 Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • operated between September 2007 and December 2015 labeled in the registry with both 'Spinal stenosis' and 'Degenerative spondylolisthesis'
  • operated on with decompression with or without an additional fusion

Who cannot join

  • operated with an anterior approach
  • had a former operation at index Level
  • was labeled with a degenerative scoliose
  • was operated in more than 2 Levels
  • was operated with non-instrumented fusion
  • operated with a standard laminectomy with removing of the posterior midline structures or operated without magnifying devices was excluded from the micro-decompression group

Trial locations and contacts

1 site in 1 country.

Norway1 site
  • Kysthospitalet i Hagevik, Orthopeadic Clinic, Haukeland University Hospital

    Bergen, Hagevik, 5217

Other trials in Norway

About this study

Official title: Less Invasive Decompression Alone as Good as Decompression Plus Instrumented Fusion for Lumbar Spinal Degenerative Spondylolisthesis at Long Term? A Pragmatic Comparative Non-inferiority Observational Study From the Norwegian Registry for Spine Surgery

In many countries a majority of patients with degenerative spondylolisthesis are operated on with decompression plus instrumented fusion, but the scientific evidence for adding fusion is controversial. To evaluate whether micro-decompression alone is as good as (non-inferior to) decompression plus instrumented fusion, a study with data from the Norwegian Registry for Spine Surgery was conducted, now the long-term follow up.

Read the detailed description

It is moderate evidence for that surgical treatment is superior non-surgical treatment for Degenerative Spondylolisthesis (DS). Question regarding the effectiveness of different surgical treatment alternatives is a controversy. The main goal for an operation is to decompress the stenotic neural elements. Based on two influential studies in the early1990's, an additional fusion procedure became more and more common and during the next decades the rate of fusion procedures as well as the complexity of the fusion procedures increased dramatically. In 2011 about 90 % of the surgeries performed in the United States included an instrumented fusion procedure. This practice has been supported by several guidelines and reviews. However, the evidence for this practice has been questioned and as a consequence of the conflicting results from two randomised controlled trial, the role of fusion again has become controversial.

According to the annual reports from Norwegian Spine Registry (NORspine), the majority of the decompression alone surgeries for DS is performed with preserving of the midline structures. These procedures are considered to be biomechanical less extensive and may result in less instability and less progression of the slip compared to a standard laminectomy.

In the now published Norwegian study (NORSTEN-DS; Clinicaltrial.gov Identifier: NCT02051374) DS the participants were randomised into micro-decompression alone and decompression plus instrumented fusion. In the observational non-inferiority cohort study the investigators evaluated the effectiveness of micro-decompression alone and decompression plus instrumented fusion among patients registered in the NORspine registry. The hypothesis was that the clinical result for the micro- decompression group is as good as the results for the instrumented fusion group, at short time (12 months after operation) and at long time (7 to 15 years after operation) for DS .

Statistics For the complete cohort of patients fulfilling the inclusion and exclusion criteria, the baseline demographics and outcome measures will be presented.

To as best as possible adjust for covariate that can bias the allocation to treatment, Propensity score matching (PSM) will be used to make the distribution of observed baseline patient characteristics in the micro-decompression group and the fusion group as similar as possible. The following parameters will be included in the calaculation of the propensity score: Age; Gender; American Society of Anesthesiologists (ASA) grade; Body Mass Index (BMI); Smoking, Oswestry Disability Index(ODI), Numeric Rating Scale for leg pain and for back pain, Euroqol 5-D (EQ5D), foraminal stenosis, degenerative disc disease, predominating back pain, number of levels operated on and neurological palsy. The PSM scores will be derived from a logistic regression model and reflect a patient's theoretical baseline probability for being instrumentally fused. Using the technique of '1:1 matching without replacement', pairs of fused and non-fused patients with a difference in propensity scores less than 0.2 in logit of the standard deviation will be formed.

In order to include data from all three time points and hence make use of all available data, Latent Growth Curve (LGC) models with Full Information Maximum Likelihood will be used for estimating the change scores and the follow-up scores for ODI ,NRS leg pain and NRS back pain. Thus, information from patients will not be excluded if data are missing at one of the follow-ups. Statistical Package for the Social Sciences (SPSS) version 24 will be used for descriptive statistics, tests for distribution of data, cross-tabulations with χ2 test, Student t-tests and Mann-Whitney U tests of group differences and linear and logistic regression modelling Mplus verion 7.3 will be used for analysing LGC models.

To control for biased estimate due to data missingness, a sensitivity analysis will be performed. With use of baseline and follow-up data as predictors for multiple imputation (MI), 10 data sets will be generated with complete follow-up scores for ODI, NRS leg pain and NRS back pain.

The sample size calculation for comparing the effectiveness of the treatments is based on the same assumption as the randomized multicentre trial on the same patient group (ClinicalTrials.gov Identifier: NCT02051374). In a non-inferiority design, with one sided testing, the investigators want to detect whether the responder rate for the micro-decompression group is less than 15 percentages lower than for the fusion group. This has to be tested by forming a 95% confidence interval (CI) for the difference of proportions (i.e. percentage of responders in the fusion group minus percentage of responders in the micro-decompression group) and has to be rejected if the upper limit of the CI is less than 15. If rejected, the conclusion will be that decompression alone is non-inferior, i.e. as good as, decompression with fusion. A 15% difference in responder rate corresponds to a number needed to treat of 7 patients (NNT = 100/15 = 6.67 [12]. Choosing a type 1 error = 0.05 and power = 0.90 gives a sample size of 160. Considering these assumptions, and adding 25% for possible dropouts, a total of 213 patients are required in each group.

To investigate the long term results, we will perform a similar study with data at long term follow-up (5 to 15 years postoperatively) including the same patients as in the primary study (one year follow-up). The patients will receive a similar questionnaire as used in the primary study. The design, primary outcome, secondary outcomes, hypothesis, hypothesis testing, non-inferiority margin and statistical methods will follow the same rules as for the primary study. When analyzing the clinical outcomes (patient reported outcome measurements) the statistician will be blinded for treatment assignment.

Being tested
Surgical treatment of Degenerative Spondylolisthesis
Keywords
Degenerative Spondylolisthesis, Treatment, Decompression alone, Instrumented fusion, Oswestry Disability Index

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Surgical treatment of Degenerative SpondylolisthesisProcedure or surgery

Study groups in NCT03469791
Study groupRoleWhat they receive
Micro-decompression aloneActive comparatorIn Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a midline-precerving decompression without fusion
Receives: Procedure: Surgical treatment of Degenerative Spondylolisthesis
Decompression and instrumented fusionActive comparatorIn Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a decompression followed by an instrumental fusion with or without an additional Cage
Receives: Procedure: Surgical treatment of Degenerative Spondylolisthesis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Responder rate assessed by ODI

    The proportion of participants with an improvement on the Oswestry Disability Index score score more than 30% from preoperative to 12 month and long term follow-up.ODI is a self-reported instrument comprising 10 sections where the patient is supposed to mark the most appropriate item.The sum score range from 0 to 100 were 100 represent the greatest impairment.

    Measured: From date of operation to 12 month follow-up. From date of operation to long-term(7-15 yrs) follow-up

Secondary outcomes (7)
  1. ODI: Mean change and mean follow-up score

    Mean change from date of operation to 3 month follow-up, from 3 to 12 month follow-up, from 12 month to long term, the mean follow-up score at 12 month and at long term follow up.

    Measured: From date of operation to 12 month follow-up and to long term follow-up (7 -15 yrs)

  2. NRS leg pain

    Mean change from date of operation to 3 month follow-up, from 3 to 12 month follow-up and the mean follow-up score at 12 month and long term (7-15yrs) for the Numeric Rating Scale [(NRS; which ranges from 0 to 10 (worst pain imaginable)] for leg pain.

    Measured: From date of operation to 12 month follow-up and long term follow up (7-15 yrs)

  3. NRS back pain

    Mean change from date of operation to 3 month follow-up, from 3 to 12 month follow-up and the mean follow-up score at 12 month and at long term (7-15 yrs)for NRS back pain

    Measured: From date of operation to 12 month follow-up and long term follow up (7-15 yrs)

  4. GPE scores

    Global Perceived Effect scale (GPE; a global assessment of patient-rated satisfaction with treatment outcome, with the answers 'completely recovered'=6, 'much improved'=5, 'slightly improved'=4, 'unchanged'=3, 'slightly worse'=2, 'much worse'=1 and 'worse than ever'=0. The GPE-responses will be trichotomised into 'substantially improved' ('completely recovered' and 'much improved'), 'slight or no change' ('slightly improved', 'unchanged' and 'slightly worse') and 'substantially deteriorated' ('much worse' and 'worse than ever')

    Measured: At 12 month follow-up and at long term follow up (7-15yrs)

  5. Hospital stay

    The length of hospital stay

    Measured: Up to 12 months

  6. Operation time

    The duration of surgery

    Measured: Perioperative

  7. Complications

    The rate of perioperative complications and adverse events registered on the surgeon form and the rate of patient-reported complications and adverse events the first 3 months postoperative.

    Measured: From date of operation to 3 month follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Mar 2018
  2. Study start1 Sep 2007
  3. Primary completion31 Dec 2017
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
Non-inferiority cohort study
Masking
None (open label)
Enrolment
426 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03469791
Sponsor's protocol ID
2014/344
Acronym
DS-registry
Status last verified
Mar 2025
First submitted
5 Mar 2018
Last updated
12 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Surgical treatment of Degenerative Spondylolisthesis in people with Degenerative Lumbar Spondylolisthesis, run by Haukeland University Hospital at 1 site in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 12 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Responder rate assessed by ODI (time frame: From date of operation to 12 month follow-up. From date of operation to long-term(7-15 yrs) follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2025; AzTrials last refreshed its copy on 30 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in